ScholarIQanswers from OpenAlex & ORCID
Markus Warmuth
ResearcherPublications, citations & collaboration network
Markus Warmuth is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Markus Warmuth have?
ScholarIQindexed works
Markus Warmuth has 186 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Markus Warmuth have?
ScholarIQcitation count
Markus Warmuth has 19,155 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Markus Warmuth?
ScholarIQh-index
Markus Warmuth has an h-index of 44 in OpenAlex.
What is the i10-index of Markus Warmuth?
ScholarIQi10-index
Markus Warmuth has an i10-index of 61 in OpenAlex.
What is the OpenAlex record for Markus Warmuth?
ScholarIQopenalex
The OpenAlex for Markus Warmuth is on the source record.
What are the most-cited papers on Markus Warmuth?
ScholarIQmost cited works
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, K. Venkatesan, Adam A. Margolin, Sung Joon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané‐Valbuena, Felipa Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying Karen Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sung Joon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank F. Sun, Auzon Steffy, AnneMarie Culazzo Pferdekamper, Allen G. Li, Sean B. Joseph, Young Ho Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo W. Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin C. Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, J. Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre‐Yves Michellys
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
Yiguo Hu, Yuhua Liu, Shawn D. Pelletier, Elisabeth Buchdunger, Markus Warmuth, Doriano Fabbro, Michael Hallek, Richard A. Van Etten, Shaoguang Li